Combined Pharmacotherapies for Cocaine Dependence

可卡因依赖的联合药物疗法

• 批准号: 7173191
• 负责人: Frances Rudnick Levin
• 金额: $ 34.65万
• 依托单位: NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7173191
• 关键词: anticonvulsants; chemotherapy; clinical research; cocaine; placebos

DESCRIPTION (provided by applicant): Cocaine-use disorders continue to be a significant public health problem in the US. Although there are no FDA-approved pharmacotherapies for cocaine use disorders, some studies of candidate medications have yielded promising results. Given the success in recent years in developing effective pharmacotherapies for alcohol, opioid, and nicotine use disorders, the development of effective pharmacotherapies for cocaine use disorders remains an important public health goal. A recent research trend in substance-use disorder pharmacotherapy is the testing of combinations of agents with different mechanisms to evaluate their potential for synergistic effects. One of the most significant efforts in this line of research is the NIAAA- funded COMBINE Study of naltrexone and acamprosate in the treatment of alcohol dependence. The combination of multiple medications with distinct mechanisms of action has long been accepted into clinical practice in psychiatry and other medical specialties. However, cocaine use disorder pharmacotherapy clinical trials have almost exclusively tested the administration of a single agent. Therefore, we are proposing combining two agents with distinct mechanisms of action that have shown promise in the treatment of cocaine use disorders to determine if the combined therapy is more effective than placebo. The proposed project is a randomized double-blind placebo-controlled trial of extended-release mixed amphetamine salts (ER-MAS) combined with topiramate for the treatment of cocaine dependence. Outpatients meeting DSM-IV criteria for cocaine dependence will enter a one-week placebo lead-in followed by a 12-week prospective, parallel group, randomized, placebo-controlled trial. Following are the specific aims of this study: 1. To determine the efficacy of ER-MAS and topiramate in promoting cocaine abstinence among cocaine- dependent patients. 2. To determine the effect of ER-MAS and topiramate on cocaine craving among cocaine-dependent patients. 3. To explore a set of related secondary outcomes (treatment retention, global functioning, and HIV risk behavior) as well as moderators and mediators potentially reflective of mechanism of action.

描述（由申请人提供）：可卡因使用障碍在美国仍然是一个重大的公共卫生问题。虽然目前还没有fda批准的药物治疗可卡因使用障碍，但一些候选药物的研究已经产生了有希望的结果。鉴于近年来在开发治疗酒精、阿片类药物和尼古丁使用障碍的有效药物疗法方面取得的成功，开发治疗可卡因使用障碍的有效药物疗法仍然是一项重要的公共卫生目标。药物使用障碍药物治疗的最新研究趋势是测试具有不同机制的药物组合，以评估其潜在的协同效应。这方面最重要的研究成果之一是NIAAA资助的纳曲酮和阿坎普罗酸治疗酒精依赖的联合研究。具有不同作用机制的多种药物的联合治疗在精神病学和其他医学专业的临床实践中早已被接受。然而，可卡因使用障碍药物治疗临床试验几乎只测试了单一药物的施用。因此，我们建议联合使用两种具有不同作用机制的药物，以确定联合治疗是否比安慰剂更有效。这两种药物在治疗可卡因使用障碍方面表现出了希望。拟议的项目是一项随机双盲安慰剂对照试验，缓释混合安非他明盐（ER-MAS）联合托吡酯治疗可卡因依赖。符合DSM-IV可卡因依赖标准的门诊患者将进入为期一周的安慰剂先导试验，随后是为期12周的前瞻性、平行组、随机、安慰剂对照试验。以下是本研究的具体目的：目的：探讨ER-MAS联合托吡酯促进可卡因依赖患者戒断的疗效。2. 目的：探讨ER-MAS和托吡酯对可卡因依赖患者可卡因渴求的影响。3. 探讨一组相关的次要结局（治疗保留、整体功能和艾滋病毒风险行为）以及可能反映作用机制的调节因子和调节因子。